Stockreport
Incyte outlines 10–13% revenue growth for 2026 amid robust pipeline expansion and new product launches [Seeking Alpha]
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations: incyte.com/ir/investor-overview.aspx
William Meury, CEO, stated that "our business exceeded expectations on three levels: total sales, Jakafi sales and our core business sales ex-Jakafi," and emphasized that "we fundamentally changed the shape and maturity of our pipeline," highlighting transition of Newsletters for Every Investor Get daily, sector-specific newsletters packed with expert insights, fresh ideas, and new opportunities. Subscribe to Newsletters Sign Up Quick Insights Key growth drivers include Jakafi, Opzelura, the hematology/oncology segment, and the advancing pipeline with 14 pivotal trials and several new launches planned. Incyte is mitigating regulatory risks by prioritizing required clinical studies and addressing competitive risks through broad formulary coverage, differentiated products, and new approvals. Management forecasts Opzelura 2026 sales between $750 million and $790 million, expects international sales growth, has taken pricing actions to improve formulary coverage, and pred
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | INCY | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
INCY alerts
INCY alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
NEWS
NEWS
- Incyte (NASDAQ:INCY) had its price target lowered by analysts at Royal Bank Of Canada from $95.00 to $92.00. They now have a "sector perform" rating on the stock.[MarketBeat]
- Incyte (NASDAQ:INCY) was given a new $102.00 price target on by analysts at Morgan Stanley.[MarketBeat]
- Incyte: Why The Market Is Overreacting To A Guidance 'Miss' [Seeking Alpha][Seeking Alpha]
- Incyte (NASDAQ:INCY) had its price target lowered by analysts at Wells Fargo & Company from $107.00 to $101.00. They now have an "equal weight" rating on the stock.[MarketBeat]
- Incyte (NASDAQ:INCY) was given a new $120.00 price target on by analysts at Stifel Nicolaus.[MarketBeat]
- More
INCY
SEC Filings
SEC Filings
- 2/10/26 - Form SCHEDULE
- 2/10/26 - Form 10-K
- 2/10/26 - Form 8-K
- INCY's page on the SEC website
- More